| 7497 | Humans |
| 5206 | Male |
| 4834 | Female |
| 3893 | Middle Aged |
| 3346 | Parkinson Disease |
| 3333 | Aged |
| 2523 | Adult |
| 959 | Severity of Illness Index |
| 945 | Magnetic Resonance Imaging |
| 942 | Aged, 80 and over |
| 893 | Antiparkinson Agents |
| 862 | Levodopa |
| 861 | Neurologic Examination |
| 738 | Brain |
| 621 | Dystonia |
| 576 | Electromyography |
| 570 | Treatment Outcome |
| 559 | Adolescent |
| 542 | Animals |
| 515 | Tremor |
| 499 | Movement Disorders |
| 472 | Neuropsychological Tests |
| 465 | Follow-Up Studies |
| 455 | Diagnosis, Differential |
| 425 | Parkinsonian Disorders |
| 399 | Deep Brain Stimulation |
| 377 | Case-Control Studies |
| 353 | Child |
| 347 | Cognition Disorders |
| 339 | Disease Progression |
| 331 | Dose-Response Relationship, Drug |
| 329 | Mutation |
| 327 | Questionnaires |
| 326 | Time Factors |
| 324 | Retrospective Studies |
| 298 | Dystonic Disorders |
| 298 | Dyskinesia, Drug-Induced |
| 293 | Young Adult |
| 289 | Analysis of Variance |
| 280 | Disability Evaluation |
| 278 | Corpus Striatum |
| 277 | Functional Laterality |
| 271 | Huntington Disease |
| 269 | Substantia Nigra |
| 268 | Myoclonus |
| 266 | Globus Pallidus |
| 259 | Double-Blind Method |
| 256 | Multiple System Atrophy |
| 255 | Subthalamic Nucleus |
| 252 | Risk Factors |
| 250 | Age of Onset |
| 243 | Chorea |
| 240 | Cerebral Cortex |
| 232 | Dopamine |
| 230 | Drug Therapy, Combination |
| 228 | Basal Ganglia |
| 226 | Tomography, Emission-Computed, Single-Photon |
| 222 | Electroencephalography |
| 220 | Brain Mapping |
| 219 | Essential Tremor |
| 216 | Reproducibility of Results |
| 214 | Genotype |
| 211 | Torticollis |
| 208 | DNA Mutational Analysis |
| 204 | Muscle, Skeletal |
| 200 | Phenotype |
| 199 | Psychomotor Performance |
| 199 | Dopamine Agonists |
| 197 | Supranuclear Palsy, Progressive |
| 197 | Quality of Life |
| 196 | Pedigree |
| 195 | Genetic Predisposition to Disease |
| 194 | Reaction Time |
| 194 | Parkinson Disease, Secondary |
| 191 | Videotape Recording |
| 189 | Motor Activity |
| 188 | Dominance, Cerebral |
| 185 | Neurons |
| 181 | Prospective Studies |
| 179 | Nerve Tissue Proteins |
| 179 | Dementia |
| 174 | Restless Legs Syndrome |
| 172 | Posture |
| 167 | Longitudinal Studies |
| 167 | Age Factors |
| 166 | Movement |
| 162 | Prevalence |
| 162 | Cohort Studies |
| 159 | Statistics, Nonparametric |
| 157 | Child, Preschool |
| 155 | Cross-Sectional Studies |
| 154 | alpha-Synuclein |
| 153 | Atrophy |
| 152 | Drug Administration Schedule |
| 150 | Reference Values |
| 150 | Botulinum Toxins, Type A |
| 150 | Activities of Daily Living |
| 148 | Cerebellum |
| 145 | Tomography, X-Ray Computed |
| 143 | Thalamus |
| 143 | Psychiatric Status Rating Scales |
| 141 | Gait Disorders, Neurologic |
| 139 | Disease Models, Animal |
| 139 | Basal Ganglia Diseases |
| 138 | Tourette Syndrome |
| 137 | Dopamine Agents |
| 137 | Botulinum Toxins |
| 135 | Electric Stimulation Therapy |
| 134 | Nerve Degeneration |
| 134 | Motor Cortex |
| 134 | Family Health |
| 133 | Gait |
| 132 | Antipsychotic Agents |
| 130 | Depression |
| 128 | Carbidopa |
| 127 | Image Processing, Computer-Assisted |
| 126 | Electrodes, Implanted |
| 123 | Dyskinesias |
| 120 | Point Mutation |
| 120 | Neural Pathways |
| 118 | Polysomnography |
| 113 | Positron-Emission Tomography |
| 112 | Putamen |
| 112 | Electric Stimulation |
| 110 | Sensitivity and Specificity |
| 109 | Motor Skills |
| 109 | Mental Status Schedule |
| 106 | Injections, Intramuscular |
| 106 | Blepharospasm |
| 105 | Brain Stem |
| 103 | Protein-Serine-Threonine Kinases |
| 102 | Gene Frequency |
| 102 | Anticonvulsants |
| 101 | Ubiquitin-Protein Ligases |
| 101 | Neurodegenerative Diseases |
| 101 | Frontal Lobe |
| 100 | History, 20th Century |
| 99 | Postural Balance |
| 98 | Statistics as Topic |
| 97 | Tomography, Emission-Computed |
| 96 | Pilot Projects |
| 95 | Predictive Value of Tests |
| 94 | Syndrome |
| 94 | Hand |
| 91 | Lewy Body Disease |
| 91 | Evoked Potentials, Motor |
| 90 | Neuromuscular Agents |
| 90 | Hypokinesia |
| 88 | United States |
| 87 | Spinocerebellar Ataxias |
| 87 | Exons |
| 85 | Radiopharmaceuticals |
| 83 | Transcranial Magnetic Stimulation |
| 83 | Cognition |
| 82 | Rats |
| 82 | Incidence |
| 82 | Genetic Testing |
| 82 | Dopamine Plasma Membrane Transport Proteins |
| 80 | Attention |
| 80 | Anti-Dyskinesia Agents |
| 80 | Alleles |
| 79 | Polymorphism, Single Nucleotide |
| 78 | Sex Factors |
| 78 | Polymorphism, Genetic |
| 76 | Hallucinations |
| 76 | Drug Combinations |
| 76 | Ataxia |
| 75 | Walking |
| 75 | Psychometrics |
| 75 | Chi-Square Distribution |
| 75 | Apomorphine |
| 74 | Tropanes |
| 74 | Regression Analysis |
| 73 | Cross-Over Studies |
| 73 | Cerebral Infarction |
| 72 | Spinal Cord |
| 72 | Receptors, Dopamine |
| 72 | Polymerase Chain Reaction |
| 72 | Nuclear Proteins |
| 72 | Mesencephalon |
| 72 | Evoked Potentials, Somatosensory |
| 71 | Muscle Rigidity |
| 71 | Motor Neurons |
| 71 | Biomechanical Phenomena |
| 70 | Postoperative Complications |
| 70 | Clinical Trials as Topic |
| 70 | Arm |
| 69 | Receptors, Dopamine D2 |
| 69 | REM Sleep Behavior Disorder |
| 69 | Pain |
| 69 | Infant |
| 68 | Lewy Bodies |
| 67 | Odds Ratio |
| 65 | Neuroprotective Agents |
| 65 | Neural Inhibition |
| 64 | Sleep Disorders |
| 63 | Video Recording |
| 63 | Trinucleotide Repeats |
| 63 | Trinucleotide Repeat Expansion |
| 63 | Neck Muscles |
| 63 | Mice |
| 63 | Hepatolenticular Degeneration |
| 63 | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine |
| 62 | Comorbidity |
| 62 | Chromosome Aberrations |
| 62 | Autonomic Nervous System Diseases |
| 61 | Muscle Contraction |
| 61 | Mental Disorders |
| 61 | Fluorodeoxyglucose F18 |
| 61 | Cerebellar Ataxia |
| 61 | Caudate Nucleus |
| 60 | tau Proteins |
| 60 | Stereotaxic Techniques |
| 60 | Olfaction Disorders |
| 60 | Leg |
| 60 | Alzheimer Disease |
| 59 | Indoles |
| 59 | History, 19th Century |
| 59 | Blinking |
| 57 | Iodine Radioisotopes |
| 57 | Genes, Dominant |
| 57 | Combined Modality Therapy |
| 56 | Randomized Controlled Trials as Topic |
| 56 | Molecular Chaperones |
| 55 | Logistic Models |
| 55 | Fatal Outcome |
| 53 | Risk |
| 53 | Neurology |
| 52 | Dystonia Musculorum Deformans |
| 52 | Depressive Disorder |
| 51 | Signal Processing, Computer-Assisted |
| 51 | Pain Measurement |
| 50 | Psychotic Disorders |
| 50 | Outcome Assessment (Health Care) |
| 50 | Nerve Net |
| 50 | Biological Markers |
| 50 | Benzothiazoles |
| 49 | Pons |
| 49 | Neurosurgical Procedures |
| 49 | Membrane Glycoproteins |
| 49 | Facial Muscles |
| 49 | Brain Diseases |
| 48 | Spinocerebellar Degenerations |
| 48 | Bromocriptine |
| 47 | Sensation Disorders |
| 47 | Membrane Transport Proteins |
| 47 | Haplotypes |
| 47 | Genetic Linkage |
| 46 | Spasm |
| 46 | ROC Curve |
| 46 | Japan |
| 46 | Heterozygote Detection |
| 46 | Handwriting |
| 46 | Gene Expression |
| 46 | Demography |
| 45 | Selegiline |
| 45 | Glycine |
| 45 | Friedreich Ataxia |
| 45 | Databases, Factual |
| 44 | Iron |
| 44 | Fingers |
| 44 | Epilepsies, Myoclonic |
| 43 | Tyrosine 3-Monooxygenase |
| 43 | Recurrence |
| 43 | Pergolide |
| 43 | Muscles |
| 43 | Diffusion Magnetic Resonance Imaging |
| 43 | Athetosis |
| 42 | Smoking |
| 42 | Observer Variation |
| 42 | Linear Models |
| 42 | Health Status |
| 42 | Confidence Intervals |
| 42 | Accidental Falls |
| 41 | Thalamic Nuclei |
| 41 | Italy |
| 41 | Carrier Proteins |
| 40 | Stereotyped Behavior |
| 40 | Reflex, Abnormal |
| 40 | Imaging, Three-Dimensional |
| 40 | Genetic Variation |
| 40 | Cues |
| 40 | Acoustic Stimulation |
| 39 | Tic Disorders |
| 39 | Spain |
| 39 | Somatosensory Cortex |
| 39 | Single-Blind Method |
| 39 | Psychomotor Disorders |
| 39 | Prognosis |
| 39 | Mutation, Missense |
| 39 | Multiple Sclerosis |
| 39 | Magnetic Resonance Spectroscopy |
| 39 | Dopamine Antagonists |
| 39 | Clonazepam |
| 39 | Chromosome Mapping |
| 39 | Chromosome Disorders |
| 39 | Asian Continental Ancestry Group |
| 39 | Administration, Oral |
| 38 | gamma-Aminobutyric Acid |
| 38 | Periodicity |
| 38 | Locomotion |
| 38 | Heart Rate |
| 38 | Head Movements |
| 38 | Executive Function |
| 38 | Anxiety |
| 37 | Synaptic Transmission |
| 37 | RNA, Messenger |
| 37 | Parietal Lobe |
| 37 | Obsessive-Compulsive Disorder |
| 37 | Health Surveys |
| 37 | France |
| 37 | Ergolines |
| 37 | DNA-Binding Proteins |
| 37 | Aging |
| 36 | Reflex, Startle |
| 36 | Protein Kinases |
| 36 | Immunohistochemistry |
| 36 | Evoked Potentials |
| 36 | Dysarthria |
| 35 | Psychophysiologic Disorders |
| 35 | Photic Stimulation |
| 35 | Orientation |
| 35 | Ocular Motility Disorders |
| 35 | Microelectrodes |
| 35 | Machado-Joseph Disease |
| 35 | Genetic Markers |
| 34 | Ultrasonography, Doppler, Transcranial |
| 34 | Sleep Stages |
| 34 | Pyramidal Tracts |
| 34 | Pregnancy |
| 34 | Olivopontocerebellar Atrophies |
| 34 | Occupational Diseases |
| 34 | Music |
| 34 | Hyperkinesis |
| 34 | Europe |
| 34 | Dihydroxyphenylalanine |
| 34 | Amantadine |
| 33 | Stroke |
| 33 | Meige Syndrome |
| 33 | History, 21st Century |
| 33 | Autopsy |
| 32 | Speech Disorders |
| 32 | Serine |
| 32 | Proportional Hazards Models |
| 32 | Prefrontal Cortex |
| 32 | Injections, Subcutaneous |
| 32 | Heterozygote |
| 32 | Germany |
| 32 | Genetic Association Studies |
| 32 | Eye Movements |
| 32 | Disorders of Excessive Somnolence |
| 32 | Clozapine |
| 32 | Cerebrovascular Circulation |
| 32 | Arousal |
| 32 | Acute Disease |
| 31 | Synucleins |
| 31 | Reflex |
| 31 | Impulse Control Disorders |
| 31 | Hand Strength |
| 31 | European Continental Ancestry Group |
| 31 | Circadian Rhythm |
| 31 | 3-Iodobenzylguanidine |
| 30 | Visual Perception |
| 30 | Ventral Thalamic Nuclei |
| 30 | Substance Withdrawal Syndrome |
| 30 | Schizophrenia |
| 30 | Multivariate Analysis |
| 30 | Macaca fascicularis |
| 30 | Freezing Reaction, Cataleptic |
| 30 | Exercise |
| 30 | Discrimination (Psychology) |
| 30 | Deglutition Disorders |
| 30 | Callithrix |
| 30 | Benzamides |
| 30 | Autoantibodies |
| 29 | Tongue |
| 29 | Sarcoglycans |
| 29 | Rats, Sprague-Dawley |
| 29 | Neuronal Plasticity |
| 29 | Neural Conduction |
| 29 | Hemifacial Spasm |
| 29 | Head |
| 29 | Fatigue |
| 29 | Cerebellar Diseases |
| 29 | Biopsy |
| 29 | Antibodies |
| 28 | Tetrabenazine |
| 28 | Temporal Lobe |
| 28 | Smell |
| 28 | Proprioception |
| 28 | Mood Disorders |
| 28 | Monoamine Oxidase Inhibitors |
| 28 | Memory |
| 28 | Intracellular Signaling Peptides and Proteins |
| 28 | Indans |
| 28 | Gambling |
| 28 | Enzyme-Linked Immunosorbent Assay |
| 28 | Drug Tolerance |
| 28 | Cross-Cultural Comparison |
| 28 | Catechols |
| 28 | Blood Pressure |
| 28 | Apraxias |
| 28 | Action Potentials |
| 27 | Stereotypic Movement Disorder |
| 27 | Sensory Thresholds |
| 27 | Nitriles |
| 27 | Mass Screening |
| 27 | Chronic Disease |
| 27 | Cerebral Hemorrhage |
| 27 | Brain Neoplasms |
| 26 | Voice Disorders |
| 26 | Thiazoles |
| 26 | Piracetam |
| 26 | Perceptual Disorders |
| 26 | Oxidative Stress |
| 26 | Long-Term Care |
| 26 | Hypertension |
| 26 | Homozygote |
| 26 | Genes, Recessive |
| 26 | Epilepsy |
| 26 | Diagnostic Imaging |
| 26 | Brazil |
| 26 | Arginine |
| 26 | Affect |
| 25 | Treatment Failure |
| 25 | Thalamic Diseases |
| 25 | Phosphotransferases (Alcohol Group Acceptor) |
| 25 | Oxidopamine |
| 25 | Oncogene Proteins |
| 25 | Neck |
| 25 | Membrane Proteins |
| 25 | Median Nerve |
| 25 | MPTP Poisoning |
| 25 | International Cooperation |
| 25 | Hemiplegia |
| 25 | Heart |
| 25 | Energy Metabolism |
| 25 | Encephalitis |
| 25 | Emotions |
| 25 | Cocaine |
| 25 | Cell Count |
| 25 | Aspartic Acid |
| 24 | Sleep |
| 24 | Sleep, REM |
| 24 | Siblings |
| 24 | Serotonin Uptake Inhibitors |
| 24 | Physical Therapy Modalities |
| 24 | Peripheral Nervous System Diseases |
| 24 | Nocturnal Myoclonus Syndrome |
| 24 | Muscle Cramp |
| 24 | Intellectual Disability |
| 24 | Infusions, Intravenous |
| 24 | Great Britain |
| 24 | Glucose |
| 24 | Gene Deletion |
| 24 | Fragile X Syndrome |
| 24 | Extremities |
| 24 | Depressive Disorder, Major |
| 24 | DNA Primers |
| 24 | Constipation |
| 24 | Body Mass Index |
| 24 | Autonomic Nervous System |
| 24 | Attention Deficit Disorder with Hyperactivity |
| 24 | Amyloid beta-Peptides |
| 23 | Tics |
| 23 | Terminology as Topic |
| 23 | Stiff-Person Syndrome |
| 23 | Saccades |
| 23 | Pregnancy Complications |
| 23 | Palatal Muscles |
| 23 | Oxygen |
| 23 | Motor Neuron Disease |
| 23 | Mitochondria |
| 23 | Inclusion Bodies |
| 23 | Homovanillic Acid |
| 23 | Genome-Wide Association Study |
| 23 | Gene Expression Regulation |
| 23 | Electrophysiology |
| 23 | Data Interpretation, Statistical |
| 23 | Compulsive Behavior |
| 23 | Baclofen |
| 23 | Apoptosis Regulatory Proteins |
| 23 | Akathisia, Drug-Induced |
| 22 | Verbal Behavior |
| 22 | Task Performance and Analysis |
| 22 | Rest |
| 22 | Receptors, N-Methyl-D-Aspartate |
| 22 | Pyrrolidines |
| 22 | Proteins |
| 22 | Piperidines |
| 22 | Magnetics |
| 22 | Linkage Disequilibrium |
| 22 | Isometric Contraction |
| 22 | Glucosylceramidase |
| 22 | Feasibility Studies |
| 22 | Factor Analysis, Statistical |
| 22 | Diagnostic and Statistical Manual of Mental Disorders |
| 22 | DNA, Mitochondrial |
| 22 | Conversion Disorder |
| 22 | Blood Glucose |
